Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHA Dynamic Volume is a hyaluronic acid-based dermal filler developed by Teoxane and commercialized by Revance Therapeutics. It is manufactured using Preserved Network Technology (PNT), a gentle, heatless crosslinking process designed to maintain the natural long-chain structure of hyaluronic acid, resulting in a gel with high dynamic strength and stretch. The product is specifically indicated for cheek augmentation and the correction of age-related midface contour deficiencies in adults aged 22 years or older. It is designed for injection into the subcutaneous to supraperiosteal layers to provide structural support and volume restoration while adapting to facial dynamics and maintaining natural-looking results both at rest and in motion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHA Dynamic Volume.